ClinicalTrials.gg
CompletedNCT03709056Updated Oct 18, 2018

A Study Evaluating the Efficacy and Safety of HSK3486

A Phase 2 interventional study of HSK3486 and Propofol in Sedation and Anesthesia for Adult Colonoscopy Procedures, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed at 8 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-10-18.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Dec 2017, registered Oct 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

A double-blind, randomized, active controlled, multi-center, parallel group study comparing HSK3486 with Propofol, in patients undergoing a colonoscopy.

02

Conditions studied

  • Sedation and Anesthesia for Adult Colonoscopy Procedures
03

In context

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Scheduled to undergo a diagnostic or therapeutic colonoscopy;
  2. Male or female patients, I\~III, aged ≥ 18 and≤ 70;
  3. (BMI) ≥ 18 and ≤ 30 kg/m2;
  4. the respiratory rate ≥10 and ≤24, SpO2 when inhaling ≥95%, SBP≥90mmHg, DBP≥60mmHg, HR≥55and ≤100;
  5. Patient can understand the procedure of this study and is willing to comply with study requirements. The patient can sign the ICF voluntarily.

Exclusion criteria

Exclusion Criteria:

  1. Patients were in general anesthesia.
  2. Patients with a known sensitivity to propofol, opioids, naloxone, eggs, soy products or a medical condition such that these agents were contraindicated.
  3. The patient has some history or evidence of increased risk of sedation or anesthesia, such as cardiovascular disease, respiratory disease, cerebrovascular disease, gastrodintestinal disease and other system disease prior to the screening and/or baseline period.
  4. Patients with a history of drug or ethanol abuse with the past 3 months.
  5. Patients with respiratory management difficulties.
  6. Patients in receipt of any drug within 30 days before screening.
  7. Patients in receipt of propofol, opioid , other sedative or anesthetic or analgesics within 72 hours before screening.
  8. Abnormal laboratory results consisting of any of the following:
  1. ≤ 1.5×109/L; 2)≤ 80×109/L; 3)≤ 90 g/L; 4)≥ 1.5×; 5) serum creatinine≥ 1.2×ULN. 9. Pregnant women or female patients with a positive serum or urine human chorionic gonadotropin pregnancy test at screening or baseline or lactating female patients.
  1. Patients with an inability to communicate well with the investigator, or deemed unsuitable according to the investigator (in each case providing a reason)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    HSK3486 0.4/0.2mg/kg ,0.5mg/kg/0.15mg/kg

    Drug: HSK3486

  • Active comparator
    Propofol 2.0/1.0mg/kg group

    Drug: Propofol

Interventions

  • HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old

  • Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.

06

What researchers measure

Primary outcomes

  1. Success of colonoscopy procedure

    Measured by completion of colonoscopy, no requirement for an alternative sedative or anesthesia drug and no requirement for more than 5 doses of study drug within any 15 minute period.

    Time frame: from the first dose of the study drug to removal of colonoscope on day 1

Secondary outcomes

  1. Time to start of procedure

    Time frame: From first dose of study drug until insertion of colonoscope on day 1

  2. The success rate of the colonoscopy procedure

    The number of patients who successfully completed the colonoscopy procedure accounted for the proportion of all patients in the dose group

    Time frame: from the first dose of the study drug to removal of colonoscope on day 1

  3. Time to fully alert

    Time frame: from the removal of colonoscopy procedure, until the first of three consecutive MOAA/S scores of 5 on day 1

  4. Time to discharge

    Time frame: from the removal of colonoscopy procedure, until the first of three consecutive Aldrete scores of more than or equal to 9 on day 1

  5. Application of study drug and alternative medication

    total dosages of study drug and alternative medication

    Time frame: during the colonoscopy procedure on day 1

07

Study locations

8 sites
  • West China Hospital, Sichuan University
    Changde, China
  • The Second Xiangya Hospital of Central South University
    Changsha, China
  • The Third Xiangya Hospital of Central South University
    Changsha, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • Shanghai Fengxian District Central Hospital
    Shanghai, China
  • The second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
  • General Hospital of Ningxia Medical University
    Yinchuan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Feb 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2018
First posted
Oct 17, 2018
StartActual
Dec 14, 2017
Primary completionActual
Feb 2, 2018
CompletionActual
Aug 9, 2018
Last update
Oct 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03709056
Responsible party
Sponsor
First posted
Oct 17, 2018
Start date
Dec 14, 2017
Primary completion
Feb 2, 2018
Completion
Aug 9, 2018
Last update
Oct 18, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion